A National Formulary for Canada
Bibliographic Data
| ID | 11969610 |
|---|---|
| Authors | AIDAN HOLLIS (0000-0001-5125-2193, corresponding author), Stephen Law (0000-0003-3184-572X), Stephen C K Law |
| Year | 2004 |
| Volume | 30 |
| Issue | 4 |
| Pages | 445-445 |
| Publication date | 2004-12-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Canadian Public Policy (JOURNAL) |
| Journal identifiers | ISSN: 0317-0861 • E-ISSN: 1911-9917 |
| Publisher | JSTOR (PUBLISHER) |
| DOI | 10.2307/3552524 |
| OpenAlex | W2025482201 |
| Language | EN |
| Citations received | 1 |
| References cited | 1 |
This article analyzes the benefits and costs of replacing Canada's ten different provincial formularies with one single national formulary. The 2002 Romanow Commission on the Future of Health Care in Canada recommended that Canada should have a National Drug Agency which would maintain a national formulary, replacing the existing provincial formularies which balkanize drug markets across Canada. This recommendation has been in part incorporated into the Common Drug Review in which the provinces (excluding Quebec) have agreed to undertake a single evaluation of all new drugs; provinces, however, retain their own formularies and decide which products to list. This balkanized approach to listing and insurance coverage of drugs substantially weakens the bargaining position of the provinces and leads to higher costs
Family medicine · Formulary · Health Systems, Economic Evaluations, Quality of Life · Healthcare Policy and Management · Medicine · Pharmaceutical Economics and Policy
| Citations per year | 0.06 |
|---|---|
| Citation span | 2010 - 2010 (1) |
| Highly cited | No |